These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1098 related articles for article (PubMed ID: 26923024)

  • 1. Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers.
    Xu L; Wu X; Li R; Chen K; Long Z; Zhang J; Guo X; Yao L;
    J Alzheimers Dis; 2016; 51(4):1045-56. PubMed ID: 26923024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
    J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multimodal Classification of Mild Cognitive Impairment Based on Partial Least Squares.
    Wang P; Chen K; Yao L; Hu B; Wu X; Zhang J; Ye Q; Guo X;
    J Alzheimers Dis; 2016 Aug; 54(1):359-71. PubMed ID: 27567818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-modality sparse representation-based classification for Alzheimer's disease and mild cognitive impairment.
    Xu L; Wu X; Chen K; Yao L
    Comput Methods Programs Biomed; 2015 Nov; 122(2):182-90. PubMed ID: 26298855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment - Beyond classical regression.
    Teipel SJ; Kurth J; Krause B; Grothe MJ;
    Neuroimage Clin; 2015; 8():583-93. PubMed ID: 26199870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.
    Hake A; Trzepacz PT; Wang S; Yu P; Case M; Hochstetler H; Witte MM; Degenhardt EK; Dean RA;
    Alzheimers Dement; 2015 Aug; 11(8):986-93. PubMed ID: 25916563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
    Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
    Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-Modality Sparse Representation for Alzheimer's Disease Classification.
    Kwak K; Yun HJ; Park G; Lee JM;
    J Alzheimers Dis; 2018; 65(3):807-817. PubMed ID: 29562503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of Alzheimer's Disease in Amnestic Mild Cognitive Impairment Subtypes: Stratification Based on Imaging Biomarkers.
    Ota K; Oishi N; Ito K; Fukuyama H; ;
    J Alzheimers Dis; 2016 Apr; 52(4):1385-401. PubMed ID: 27079727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
    Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
    PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Classification Algorithm by Combination of Feature Decomposition and Kernel Discriminant Analysis (KDA) for Automatic MR Brain Image Classification and AD Diagnosis.
    Elahifasaee F; Li F; Yang M
    Comput Math Methods Med; 2019; 2019():1437123. PubMed ID: 32082407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
    JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-modal discriminative dictionary learning for Alzheimer's disease and mild cognitive impairment.
    Li Q; Wu X; Xu L; Chen K; Yao L; Li R
    Comput Methods Programs Biomed; 2017 Oct; 150():1-8. PubMed ID: 28859825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.
    Dukart J; Sambataro F; Bertolino A
    J Alzheimers Dis; 2016; 49(4):1143-59. PubMed ID: 26599054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease.
    Ota K; Oishi N; Ito K; Fukuyama H; ;
    J Neurosci Methods; 2015 Dec; 256():168-83. PubMed ID: 26318777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
    Tosun D; Schuff N; Jagust W; Weiner MW;
    Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.